吗替麦考酚酯与环孢素A治疗系统性红斑狼疮继发血小板减少的疗效对比被引量：2

Comparison of therapeutic effects of mycophenolate mofetil and cyclosporine A on thrombocytopenia secondary to systemic lupus erythematosus

暂未订购

导出

摘要目的比较吗替麦考酚酯与环孢素A治疗系统性红斑狼疮继发血小板减少症的疗效。方法将我科2012年4月～2017年2月收治的48例系统性红斑狼疮患者,随机分为MMF组26例和CsA组22例。MMF组采用激素联合吗替麦考酚酯治疗,CsA组采用激素联合环孢素A治疗。观察两组患者治疗前和治疗6个月后血小板数目变化、SLEDAI评分变化及不良反应的发生情况。结果 MMF组血小板数目改善、尿蛋白下降、SLEDAI指数下降有效率及疗效均优于CsA组,差异有统计学意义(P<0.05)。结论吗替麦考酚酯治疗SLE所致血小板减少,疗效显著,副作用更少,值得临床推广应用。

作者马新史晓飞武新峰王飞

机构地区河南科技大学第一附属医院风湿免疫科

出处《现代诊断与治疗》 CAS 2019年第2期176-178,共3页 Modern Diagnosis and Treatment

关键词系统性红斑狼疮吗替麦考酚酯环孢素A 血小板减少

分类号 R593.24 [医药卫生—内科学] R558 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献2

1陈樱花,刘正钊,杨柳,章海涛,刘志红,胡伟新.激素联合吗替麦考酚酯治疗抗中性粒细胞胞质抗体相关血管炎肾脏损害患者的远期预后[J].肾脏病与透析肾移植杂志,2014,23(4):307-313. 被引量：12
2傅鹏,原爱红,于建平,王金花,吴海洋,崔若兰.吗替麦考酚酯联合激素治疗特发性膜性肾病36个月的前瞻对照性研究[J].第二军医大学学报,2012,33(3):270-273. 被引量：11

二级参考文献15

1HU Wei-xin,LIU Zhi-hong,LIU Chun-bei,TANG Zheng,WANG Qing-wen,CHEN Hui-ping,LI Lei-shi.Prognosis of microscopic polyangiitis with renal involvement:report of 60 Chinese patients[J].Chinese Medical Journal,2005(24):2089-2092. 被引量：12
2du Buf-Vereijken P W G,Branten A J W,Wetzels J F M.Idio-pathic membranous nephropathy:outline and rationale of treatmentstrategy[J].Am J Kidney Dis,2005,46:1012-1029.
3Chan T M,Lin A W,Tang S C,Qian J Q,Lam M F,Ho Y W,et al.Prospective controlled study on mycophenolate mofetil and prednis-olone in the treatment of membranous nephropathy with nephroticsyndrome[J].Nephrology,2007,12:576-581.
4Dimkovic N,Jovanovic D,Kovacevic Z,Rabrenovic V,Nesic V,Savin M,et al.Mycophenolate mofetil in high-risk patients withprimary glomeruloneohritis:results of a 1-year prospective study[J].Nephron Clin Pract,2009,111:c189-c196.
5Branten A J,du Buf-Vereijken P W,Vervloet M,Wetzels J F.My-cophenolate mofetil in idiopathic membranous nephropathy:a clinicaltrial with comparison to a historic control group treated with cyclo-phosphamide[J].Am J Kidney Dis,2007,50:248-256.
6Troyanov S,Wall C,Miller J,Scholey J,Cattran D C.Idiopathicmembranous nephropathy.Definition and relevance of partial remis-sion[J].Kidney Int,2004,66:1199-1205.
7Ponticelli C,Altieri P,Scolari F,Passerini P,Roccatello D,CesanaB,et al.A randomized study comparing methyprednisolone pluschlorambucil versus methylprednisolone plus cyclophosphamide inidiopathic membranous nephropathy[J].J Am Soc Nephrol,1998,9:444-450.
8Dussol B,Morange S,Burtey S,Indreies M,Cassuto E,Mourad G,et al.Mycophenolate mofetil monotherapy in membranous neohropa-thy:a 1-year randomized controlled trial[J].Am J Kidney Dis,2008,52:699-705.
9Sahin G M,Sahin S,Kantarci G,Ergin H.Mycophenolate mofetiltreatment for therapy-resistant glomerulopathies[J].Nephrology,2007,12:285-288.
10Miller G,Zimmerman RⅢ,Radharishnan J,Appel G.Use of myco-phenolate mofetil in resistant membranous nephropathy[J].Am JKidney Dis,2000,36:250-256.